These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 32460804)

  • 21. Clinical exigencies, psychosocial realities: negotiating HIV pre-exposure prophylaxis beyond the cascade among gay, bisexual and other men who have sex with men in Canada.
    Newman PA; Guta A; Lacombe-Duncan A; Tepjan S
    J Int AIDS Soc; 2018 Nov; 21(11):e25211. PubMed ID: 30474351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing the acceptability of, adherence to and preference for a dual prevention pill (DPP) for HIV and pregnancy prevention compared to oral pre-exposure prophylaxis (PrEP) and oral contraception taken separately: protocols for two randomised, controlled, cross-over studies in South Africa and Zimbabwe.
    Friedland BA; Mgodi NM; Palanee-Phillips T; Mathur S; Plagianos MG; Bruce IV; Lansiaux M; Murombedzi C; Musara P; Dandadzi A; Reddy K; Ndlovu N; Zulu SK; Shale LR; Zieman B; Haddad LB
    BMJ Open; 2024 Mar; 14(3):e075381. PubMed ID: 38479746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pregnant women's perceptions of risks and benefits when considering participation in vaccine trials.
    Jaffe E; Lyerly AD; Goldfarb IT
    Vaccine; 2020 Oct; 38(44):6922-6929. PubMed ID: 32893036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Key barriers and enablers associated with uptake and continuation of oral pre-exposure prophylaxis (PrEP) in the public sector in Zimbabwe: Qualitative perspectives of general population clients at high risk for HIV.
    Gombe MM; Cakouros BE; Ncube G; Zwangobani N; Mareke P; Mkwamba A; Prescott MR; Bhatasara T; Murwira M; Mangwiro AZ; Prust ML
    PLoS One; 2020; 15(1):e0227632. PubMed ID: 31931514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reaching at-risk women for PrEP delivery: What can we learn from clinical trials in sub-Saharan Africa?
    Stankevitz K; Schwartz K; Hoke T; Li Y; Lanham M; Mahaka I; Mullick S
    PLoS One; 2019; 14(6):e0218556. PubMed ID: 31226165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship Type and Use of the Vaginal Ring for HIV-1 Prevention in the MTN 020/ASPIRE Trial.
    Pleasants E; Tauya T; Reddy K; Mirembe BG; Woeber K; Palanee-Phillips T; Zimba C; Atujuna M; Montgomery ET;
    AIDS Behav; 2020 Mar; 24(3):866-880. PubMed ID: 31111297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cofactors of Partner HIV Self-testing and Oral PrEP Acceptance Among Pregnant Women at High Risk of HIV in Kenya.
    Ngumbau NM; Neary J; Wagner AD; Abuna F; Ochieng B; Dettinger JC; Gómez L; Marwa MM; Watoyi S; Nzove E; Pintye J; Baeten JM; Kinuthia J; John-Stewart G
    J Acquir Immune Defic Syndr; 2024 Mar; 95(3):238-245. PubMed ID: 38408215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. "
    Mwongeli N; Wagner AD; Dettinger JC; Pintye J; Brown Trinidad S; Awuor M; Kimemia G; Ngure K; Heffron RA; Baeten JM; Mugo N; Bukusi EA; Kinuthia J; Kelley MC; John-Stewart GC; Beima-Sofie KM
    J Int Assoc Provid AIDS Care; 2022; 21():23259582221111068. PubMed ID: 35776525
    [No Abstract]   [Full Text] [Related]  

  • 29. Acceptability and use of a dapivirine vaginal ring in a phase III trial.
    Montgomery ET; van der Straten A; Chitukuta M; Reddy K; Woeber K; Atujuna M; Bekker LG; Etima J; Nakyanzi T; Mayo AJ; Katz A; Laborde N; Grossman CI; Soto-Torres L; Palanee-Phillips T; Baeten JM;
    AIDS; 2017 May; 31(8):1159-1167. PubMed ID: 28441175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acceptability of lifelong treatment among HIV-positive pregnant and breastfeeding women (Option B+) in selected health facilities in Zimbabwe: a qualitative study.
    Chadambuka A; Katirayi L; Muchedzi A; Tumbare E; Musarandega R; Mahomva AI; Woelk G
    BMC Public Health; 2017 Jul; 18(1):57. PubMed ID: 28743251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. "I Did Not Want to Give Birth to a Child Who has HIV": Experiences Using PrEP During Pregnancy Among HIV-Uninfected Kenyan Women in HIV-Serodiscordant Couples.
    Pintye J; Beima-Sofie KM; Kimemia G; Ngure K; Trinidad SB; Heffron RA; Baeten JM; Odoyo J; Mugo N; Bukusi EA; Kelley MC; John-Stewart GC
    J Acquir Immune Defic Syndr; 2017 Nov; 76(3):259-265. PubMed ID: 28777265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lessons learned from the PMTCT program in Swaziland: challenges with accepting lifelong ART for pregnant and lactating women - a qualitative study.
    Katirayi L; Chouraya C; Kudiabor K; Mahdi MA; Kieffer MP; Moland KM; Tylleskar T
    BMC Public Health; 2016 Oct; 16(1):1119. PubMed ID: 27776495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protocol for a longitudinal study to evaluate the use of tenofovir-based PrEP for safer conception and pregnancy among women in South Africa.
    Matthews LT; Jaggernath M; Kriel Y; Smith PM; O'Neil K; Haberer JE; Hendrix C; Baeten JM; Ware NC; Wirth K; Psaros C; Bangsberg DR; Smit JA
    BMJ Open; 2019 Jul; 9(7):e027227. PubMed ID: 31350241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. "You Never Know What Could Happen": Women's Perspectives of Pre-Exposure Prophylaxis in the Context of Recent Intimate Partner Violence.
    Willie TC; Keene DE; Kershaw TS; Stockman JK
    Womens Health Issues; 2020; 30(1):41-48. PubMed ID: 31537431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Male Partner Involvement on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III HIV Prevention Trial.
    Roberts ST; Nair G; Baeten JM; Palanee-Philips T; Schwartz K; Reddy K; Kabwigu S; Matovu Kiweewa F; Govender V; Gaffoor Z; Singh N; Siva S; Naidoo K; Montgomery ET;
    AIDS Behav; 2020 May; 24(5):1432-1442. PubMed ID: 31667678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stated product formulation preferences for HIV pre-exposure prophylaxis among women in the VOICE-D (MTN-003D) study.
    Luecke EH; Cheng H; Woeber K; Nakyanzi T; Mudekunye-Mahaka IC; van der Straten A;
    J Int AIDS Soc; 2016; 19(1):20875. PubMed ID: 27247202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identifying factors that influence pregnancy intentions: evidence from South Africa and Malawi.
    Evens E; Tolley E; Headley J; McCarraher DR; Hartmann M; Mtimkulu VT; Manenzhe KN; Hamela G; Zulu F;
    Cult Health Sex; 2015; 17(3):374-89. PubMed ID: 25353696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reactions and Receptivity to Framing HIV Prevention Message Concepts About Pre-Exposure Prophylaxis for Black and Latino Men Who Have Sex with Men in Three Urban US Cities.
    Mimiaga MJ; Closson EF; Battle S; Herbst JH; Denson D; Pitts N; Holman J; Landers S; Mansergh G
    AIDS Patient Care STDS; 2016 Oct; 30(10):484-489. PubMed ID: 27749110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Male partners' influence on women's acceptance and use of PrEP products across two high HIV-burdened districts in South Africa.
    Mbewe L; Govender E
    Afr J AIDS Res; 2020 Jul; 19(2):93-100. PubMed ID: 32320329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The landscape for HIV pre-exposure prophylaxis during pregnancy and breastfeeding in Malawi and Zambia: A qualitative study.
    Zimba C; Maman S; Rosenberg NE; Mutale W; Mweemba O; Dunda W; Phanga T; Chibwe KF; Matenga T; Freeborn K; Schrubbe L; Vwalika B; Chi BH
    PLoS One; 2019; 14(10):e0223487. PubMed ID: 31584987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.